Press Release Issued Under the Early Warning System/Sale of Shares of Nymox Pharmaceutical Corporation
MONTREAL, April 2, 2013 (GLOBE NEWSWIRE) -- This press release is being disseminated as required by the early warning requirements of applicable Canadian securities laws. Paul Averback MD of 9900 Cavendish Blvd. Suite 306, St-Laurent, Quebec, announces today that he has sold in a private transaction for financial planning purposes 465,000 common shares of Nymox Pharmaceutical Corporation (NYMX) ("Nymox") for a total consideration of $2,032,092 ($1,999,500 US). The sale represents approximately 1.38 % of the shares of Nymox issued and outstanding. Dr. Averback has no further intention to acquire or sell securities of the Corporation at this time. As a result of this sale, Dr. Averback continues to own and control 11,774,914 shares of Nymox or approximately 34.9 % of the shares of Nymox issued and outstanding. An additional 607,031 shares of Nymox (approximately 1.8 %) are owned by a family trust of which Dr. Averback is a trustee. Dr. Averback is subject to the early warning requirements for this transaction because he is a control person of Nymox by virtue of the fact that he owns more than 20% of the outstanding shares of Nymox. The sale relies on the prospectus exemption contained in Section 2.3 of Regulation 45-106 - Prospectus and Registration Exemptions. Nymox's common shares are listed on the NASDAQ Exchange under the symbol "NYMX".
CONTACT: Paul Averback Tel: (514) 332-3222Source: Nymox Pharmaceutical Corporation 2013 GlobeNewswire, Inc.